AstraZeneca Notches FTC Approval For $39B Alexion Deal
The Federal Trade Commission on Friday approved AstraZeneca's planned $39 billion merger with Alexion Pharmaceuticals Inc. after the drugmakers gave the FTC more time to scrutinize the deal....To view the full article, register now.
Already a subscriber? Click here to view full article